Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
Nat Med
; 28(11): 2388-2397, 2022 11.
Article
in En
| MEDLINE
| ID: mdl-36202997
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19
Limits:
Humans
Language:
En
Journal:
Nat Med
Journal subject:
BIOLOGIA MOLECULAR
/
MEDICINA
Year:
2022
Type:
Article
Affiliation country:
United States